CYCLOSPORINE-ASSOCIATED HYPERTENSION IN CARDIOPULMONARY TRANSPLANTATION
- 1 September 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 48 (3) , 428-429
- https://doi.org/10.1097/00007890-198909000-00015
Abstract
In a retrospective review of fifty heart, lung, and heart-lung recipients receiving cyclosporine, forty-six (92%) were hypertensive. This hypertension was managed with either prazosin (n=29) or nifedipine (n=17). Renal function was assessed by creatinine clearance estimation and found to be significantly better in those patients receiving nifedipine. (creatinine clearance=60 ml/min [SEM 5.7] vs. 49 ml/min [SEM 2.7]: P < 0.05) This observation suggests that nifedipine should be the drug of choice for the treatment of cyclocporine-associated hypertension in cardic and pulmonary transplant recipients.This publication has 7 references indexed in Scilit:
- Cyclosporin A in Cardiac Transplantation: Medium-term Results in 62 PatientsThe Annals of Thoracic Surgery, 1988
- PROTECTION AGAINST CYCLOSPORINE-INDUCED IMPAIRMENT OF RENAL MICROCIRCULATION BY VERAPAMIL IN MICETransplantation, 1988
- Mitochondrial Respiratory and Calcium StudiesAnnals of Surgery, 1987
- Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicityKidney International, 1987
- Effect of beta blockade on exercise response after cardiac transplantation.Heart, 1983
- Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.Journal of Clinical Investigation, 1981
- Atherosclerosis: Prevention by Agents Not Affecting Abnormal Levels of Blood LipidsScience, 1981